Podcasts about Malignancy

Speaker: Adam GodshallSeries: "Respectable Sins" and SanctificationText: James 1; Numbers 13-14Theme: The Malignancy of Sin

In this interview Xander is joined by the guys in Malignancy before their show at The Brass Mug in Tampa! Excerpts from the Malignancy track "Existential Dread" (2024) used with permission from the artist. Check out Malignancy's music at https://www.youtube.com/@MalignancyNY Purchase music and merchandise from Malignancy at https://malignancy.bandcamp.com/music SOCIAL LINKS: Twitter: https://twitter.com/metaldebate/ Facebook: https://www.facebook.com/thegreatmetaldebate/ Instagram: https://www.instagram.com/metaldebate/ The Great Metal Debate Podcast: https://podcasts.apple.com/us/podcast/the-great-metal-debate-podcast/id1037874814 https://soundcloud.com/thegreatmetaldebate CONTACT Business email: TheGreatMetalDebate@gmail.com

Full article: Bosniak Classification of Cystic Renal Masses Version 2019: Proportion of Malignancy by Class and Subclass—Systematic Review and Meta-Analysis Aric Berning, MD, discusses the AJR article by McGrath et al. that provides a meta-analysis of malignancy proportions for Bosniak classification version 2019, stratified by class and subclass.

Commentary by Dr. Lorenzo Gervaso

In this episode of Rash Decisions, hosts Dr George Moncrieff and Dr Roger Henderson delve into actinic keratoses (AKs), also known as solar keratoses. With expert insights, they discuss the nature of these common sun-induced lesions, their role as markers of both UV exposure and damage, along with practical approaches to diagnosis.  Key Takeaways:  How to differentiate AKs from other keratotic lesions, including Bowen's disease, keratoacanthoma and squamous cell carcinoma (SCC) The significance of clinical grading and the concept of "field cancerization" Practical tips for dermatoscopic evaluation and deciding when to refer patients.  Tune in to enhance your understanding of AKs and how the majority can be managed within primary care settings.  Thank you to our kind sponsor AproDerm, who provide a comprehensive range of quality emollients designed for the management of dry skin conditions, including eczema, psoriasis and ichthyosis.   To simplify the process of finding the most suitable emollient for each patient, they have developed a remarkable solution: the AproDerm Emollient Starter Pack. This pack conveniently combines all four of their emollients in a single prescription, enabling patients to identify their ideal emollient more efficiently, aiding both compliance and adherence.   Find out more: https://aproderm.com/aproderm-emollient-starter-pack/    LI: https://www.linkedin.com/company/fontus-health-ltd/   IG: https://www.instagram.com/aproderm/  Got some feedback for us? Please rate and review Rash Decisions to help us keep creating educational podcasts for you.   Is there a dermatology topic you'd like us to explore? Email us at info@aproderm.com, and we'll do our best to cover it.  The views expressed in this podcast are of Dr George Moncrieff and Dr Roger Henderson. Fontus Health has not influenced, participated, or been involved in the programme, materials, or delivery of educational content. 

Host: Darryl S. Chutka, M.D. Guest: Aaron M. Potretzke, M.D. Today, we're airing a popular episode from Season 2 of Mayo Clinic Talks!  Happy Holidays! Microscopic hematuria, and less commonly gross hematuria, are conditions commonly seen by the primary care provider. Malignancy is the most ominous cause of hematuria. Fortunately, other causes are much more likely. Since this is a relatively common health condition, when should we investigate hematuria and what should the evaluation consist of? How do we evaluate a patient's risk for urinary tract malignancy? Dr. Aaron Potretzke, a urologist at Mayo Clinic, joins us to discuss these questions. Connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

IBD Drive Time: Jordan Axelrad, MD, on Treating Patients With IBD and Malignancy by Gastroenterology Learning Network

Rheumatologists Dr. Jeffrey Curtis and Dr. Jon Giles discuss the risk of comorbidities that can occur as a consequence of uncontrolled inflammation in RA

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Epistemic states as a potential benign prior, published by Tamsin Leake on August 31, 2024 on The AI Alignment Forum. Malignancy in the prior seems like a strong crux of the goal-design part of alignment to me. Whether your prior is going to be used to model: processes in the multiverse containing a specific "beacon" bitstring, processes in the multiverse containing the AI, processes which would output all of my blog, so I can make it output more for me, processes which match an AI chatbot's hypotheses about what it's talking with, then you have to sample hypotheses from somewhere; and typically, we want to use either solomonoff induction or time-penalized versions of it such as levin search (penalized by log of runtime) or what QACI uses (penalized by runtime, but with quantum computation available in some cases), or the implicit prior of neural networks (large sequences of multiplying by a matrix, adding a vector, and ReLU, often with a penalty related to how many non-zero weights are used). And the solomonoff prior is famously malign. (Alternatively, you could have knightian uncertainty about parts of your prior that aren't nailed down enough, and then do maximin over your knightian uncertainty (like in infra-bayesianism), but then you're not guaranteed that your AI gets anywhere at all; its knightian uncertainty might remain so immense that the AI keeps picking the null action all the time because some of its knightian hypotheses still say that anything else is a bad idea. Note: I might be greatly misunderstanding knightian uncertainty!) (It does seem plausible that doing geometric expectation over hypotheses in the prior helps "smooth things over" in some way, but I don't think this particularly removes the weight of malign hypotheses in the prior? It just allocates their steering power in a different way, which might make things less bad, but it sounds difficult to quantify.) It does feel to me like we do want a prior for the AI to do expected value calculations over, either for prediction or for utility maximization (or quantilization or whatever). One helpful aspect of prior-distribution-design is that, in many cases, I don't think the prior needs to contain the true hypothesis. For example, if the problem that we're using a prior for is to model processes which match an AI chatbot's hypotheses about what it's talking with then we don't need the AI's prior to contain a process which behaves just like the human user it's interacting with; rather, we just need the AI's prior to contain a hypothesis which: is accurate enough to match observations. is accurate enough to capture the fact that the user (if we pick a good user) implements the kind of decision theory that lets us rely on them pointing back to the actual real physical user when they get empowered - i.e. in CEV(user-hypothesis), user-hypothesis builds and then runs CEV(physical-user), because that's what the user would do in such a situation. Let's call this second criterion "cooperating back to the real user". So we need a prior which: Has at least some mass on hypotheses which correspond to observations cooperate back to the real user and can eventually be found by the AI, given enough evidence (enough chatting with the user) Call this the "aligned hypothesis". Before it narrows down hypothesis space to mostly just aligned hypotheses, doesn't give enough weight to demonic hypothesis which output whichever predictions cause the AI to brainhack its physical user, or escape using rowhammer-type hardware vulnerabilities, or other failures like that. Formalizing the chatbot model First, I'll formalize this chatbot model. Let's say we have a magical inner-aligned "soft" math-oracle: Which, given a "scoring" mathematical function from a non-empty set a to real numbers (not necessarily one that is tractably ...

IBD Drive Time: Jordan Axelrad, MD, on IBD and Malignancy by Gastroenterology Learning Network

Canadian legends Rush are obviously huge around the RAM offices. And our own Aaron is a badass bassist as well. So of course we both got sucked right into the Paramount + mini series "Geddy Lee Asks 'Are Bass Players People Too' ". The bassist extraordinaire spends time with four major music movers and shakers that strum the four strings. The program sent our imaginations into overdrive. This week we fantasy book our own Season Two. Our picks range from some all time greats to underground underdogs to Lemmy (??!!). In our "News, Views and Tunes", we discuss Gojira at The Olympics. Musically, we crank some Ironflame, Tokyo Blade, Poison Idea, Malignancy, Helms Deep, Warlust and introduce Florida trad metallers Living Fast in our "Indie Spotlight". Horns Up!

Ep. 189 - Malignancy by Cali Death Podcast

To abruptly switch gears from our Very Special Episode earlier this week, we deliver reviews of the newest installments from two tech death giants. Ulcerate is back with their seventh full-length record which shows the band committing even more fully to the elements of post-rock, black metal, and textured drone which have helped define their sound- but have they strayed too far from the path? Pitted against them is the mutated monstrosity Malignancy's fourth full-length, which seeks to bring their sound a bit closer to the center of death metal while leaving their whiplashing, wild style of technicality intact- but can they maintain their vicious edge? YOU WOULD LIKE TO KNOW MORE. 0:00:00 - Intro 0:01:56 - Ulcerate - Cutting the Throat of God (Debemur Morti Productions) 0:54:35 - Interlude - The Brass - “Treading Water,” fr. the Rugged Cross EP (Independent, 2015) 0:58:44 - Malignancy - …Discontinued (Willowtip Records) 1:40:43 - Outro - Copremesis - “A Poem” fr. Muay Thai Ladyboys (Paragon Records, 2008) Terminus links: Terminus on Youtube Terminus on Patreon Terminus on Instagram Terminus on Facebook thetrueterminus@gmail.com

Welcome back to The Great Metal Debate podcast. Today we are talking about the fourth full-length studio album by the New York brutal tech death band Malignancy titled ...Discontinued, which was dropped on June 14th through Willowtip Records. This is the band's first album in 12 years so this certainly calls for celebration. For a band that has been around since 1992, you would think that they would have much more albums in their discography but, I guess some bands like to really take the time with their craft. Before diving into this new record track by track, I'm going point out a major similarity that I've always noticed about this band. Particularly with the vocalist Danny Nelson having a nearly identical sounding voice to Ross Dolan from Immolation. I had often wondered if Malignancy was a side project band, which would make a lot of sense seeing as how both bands are from Yonkers! The answer is no, Danny and Ross are two different people. However, Danny had done vocals for Mortal Decay's 2013 album The Blueprint For Blood Spatter. When I looked up the names of the band members, I had to do a double take when I saw the bass player. At first I thought it said Alex Webster from Cannibal Corpse, but nope, the new bass player is Alex Weber. Haha, not Webster. Coincidentally enough, guess where Cannibal Corpse originally started. You guessed it, New York. Except they formed in Buffalo. According to Metal-Archives, Alex Weber has played live for Defeated Sanity and Obscura. Guitarist Ron Kachnic has also been in Pyrexia, Demolition Hammer and Mortician! Mike Heller has been the drummer for multiple bands including System Divide which is Sven from Aborted's side project band. Despite not advertising as such, Malignancy IS a super group. Kicking things off we have the first track titled "Existential Dread". As you listen to this album, you can feel Danny's lips press against the microphone as he delivers his powerful vocals. You can tell he definitely uses his diaphragm to produce such a monstrous tone. Watch a few live videos of them and you can witness for yourself Danny's commanding stage presence too. "Purity of Purpose" was the first single released for this album about 2 months beforehand. I remembered as soon as I heard it, I immediately looked up the full-length release date and album title just to add it to my list. Judging from that track alone, I knew I had to review it. The second single "Biological Absurdity" was uploaded a month later and it of course blew me away. Both of these songs were aired on YouTube as official tracks but we haven't been treated to a music video yet. I have found myself jamming this album front to back since its release a little over a week ago and I gotta say, I'm impressed! I mean, Malignancy never disappoints. This album is absolutely killer and one of the finest examples of your standard death metal. Bad ass death metal albums without an overly unique pizazz quality about them are still more than capable of getting a good rating out of me. This is definitely one of the better straight forward death metal albums I've heard in 2024 so far. With that being said, I'm feeling a nice 8/10 rating. Malignancy has been kickin around in the underground scene since I was a 1-year-old. They've gone through a few line-up changes here and there but have held strong as a band for the past three decades. Their popularity may not be up on the same level as many other bands but they deserve a lot of credit, respect and most of all support. You can buy their merch ... at pretty much any online metal merch outlet. The most obvious choice would be bandcamp, but they also have merch at primitiverecordings.com, hellsheadbangers.com and indiemerch.com. Of course, if you get lucky enough to see them live; they definitely have a merch table and I hear that they are usually at their stand before and after a show. So don't be shy, go say hi and if nothing else, throw them a few bucks in their tip jar.

On this week's episode, Jon and Brandon discuss new releases from Charli XCX, Peggy Gou, KAYTRANADA, RM, NxWorries, The Early November, Malignancy, Vomit the Soul, Swelling Repulsion and more!   Intro Music by Anthony Reeder   Show Notes: Link To Weekly Rotating Playlist: https://open.spotify.com/show/6EE5pohSvSjm5ZFQf45iv1?si=32cab828e94d4a24

Immunotherapeutic approaches, including CAR T-cells and bispecific antibodies, have become well-established in later lines of non-Hodgkin lymphoma (NHL) treatment. CAR... The post The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies appeared first on VJHemOnc.

This week on the one-year anniversary of The Beat, Editor in Chief Joel Dunning speaks with Professor Paul Sergeant about the future of education in cardiothoracic surgery. In addition, Joel discusses trends in SAVR after TAVR, microplastics in cardiovascular events, and fibrous tumors of the pleura. He also highlights the three winners of the Resident Video Competition, including rib resection for thoracic outlet syndrome, a robotic segmentectomy, and a hypertrophic obstructive cardiomyopathy. Before saying goodbye, he discusses upcoming events in CT surgery. JANS Items Mentioned Cardiac Surgery After Transcatheter Aortic Valve Replacement: Trends and Outcomes  Microplastics and Nanoplastics in Atheromas and Cardiovascular Events  Solitary Fibrous Tumors of the Pleura: Do We Need a Different Perspective on Malignancy?  CTSNet Content Mentioned First Place: Open Cervical and Robotic First Rib Resections for Neurogenic Thoracic Outlet Syndrome  Second Place: Robotic Assisted Right Apical S1 Anatomical Segmentectomy for NSCLC Third Place: Hypertrophic Obstructive Cardiomyopathy: Anatomical Substratum for Tailored Surgical Correction Other Items Mentioned CTSNet Events Calendar Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

S10E260: Soundtrack for the Eclipse Lessons people wish they learned sooner, bizarre celebrity facts, sex stories, eclipse beliefs, did you know facts, a death row conversation, and heavy metal for your filthy earballs! (00:00:00) - Intro (00:00:57) - Malignancy, SONG: Purity of Purpose (00:04:46) - Deal with God, SONG: Imposter (00:07:06) - Conversation 1 (00:15:31) - Black Wound, SONG: Trench Blast (00:20:00) - Pantheon Omega, SONG: Invokation to War (00:24:42) - Conversation 2 (00:32:32) - Helms Deep, SONG: Serpent's Eye (00:36:17) - Abreaktion, SONG: Broken Promises (00:40:25) - Tusenårseken, SONG:Fattigdomens Köttkvarn (00:46:16) - Conversation 3 (00:52:56) - Grandma's Pantry: Abstrakt Algebra, SONG: Stigmata (00:58:28) - Conversation 4 (01:08:42) - GRAVKVADE, SONG: En Himlakropps Dödsbädd (01:17:06) - ARISTARCHOS, SONG: Oath: Dispersal of the Spectral Awning in Perpetual Flame (01:21:16) - Diabolic Oath, SONG: Rusted Madness Tethering Misbegotten Haruspices Labels: Willowtip Records, Chaos Records, Nameless Grave Records, Transylvanian Recordings, Vendetta Records, Sentient Ruin Laboratories

Episode One, Part Two of the “Real World LDRT” miniseries (sponsored by Xstrahl) circles back to the 1940s and the extraordinary flaws of the "linear no threshold" (LNT) model of radiation risk. We explore backroom deals, handshake science, corporate greed, regulatory capture, hormesis, OSHA violations, putting radium in the throats of 2.5 million children...you know, the regular, everyday stuff. Why? Because a common hesitation to deploying LDRT for arthritis is the risk of the treatment itself causing cancer. Spoiler alert: there has never been a case of secondary malignancy from therapeutic radiation below a magical threshold dose. And LDRT stays below that threshold. Don't believe me? That's why this miniseries exists! Relevant papers and sources at ⁠http://u.pc.cd/OhN⁠ Brought to you in part by Xstrahl, modern manufacturers of orthovoltage devices. Visit them at ⁠https://xstrahl.com/⁠ OOTB, produced by Photon Media, is made possible by Cold Light Legacy, a 501(c)(3) nonprofit that thrives on community support. jason@coldlight.org --- Support this podcast: https://podcasters.spotify.com/pod/show/radmed/support

Dr. Erica Golemis is a Professor, Deputy Chief Science Officer, Co-Leader of the Molecular Therapeutics Program, and Director of the High Throughput Facility at the Fox Chase Cancer Center in Philadelphia. In addition, Erica is an adjunct faculty member at the University of Pennsylvania, Drexel University School of Medicine, and the Temple University Lewis Katz School of Medicine. For most of her scientific career, Erica has been conducting cancer research. Her recent work investigates why some cancers are particularly malignant. Erica's research examines what genes cause cancer to change and progress, whether there are genes that can be targeted directly with different treatments to reverse this process, and if there is a therapeutic time window in which they could potentially reverse this process. When Erica finds free time, one thing she loves to do is read. She reads broadly and has been an avid reader since her early childhood. Erica also has fun attending theatre performances. There are multiple excellent theaters in her home city of Philadelphia, and she especially enjoys shows by British playwright Tom Stoppard. She completed her undergraduate studies in biology and English at Bryn Mawr College and was awarded her PhD in biology from the Massachusetts Institute of Technology. Afterwards, Erica conducted postdoctoral research at the Massachusetts General Hospital Department of Molecular Biology and Harvard Medical School department of Genetics before joining the Fox Chase Cancer Center. In this interview, Erica speaks about her experiences in both life and science.

In this week's episode we'll discuss the findings from a prospective trial of TCRαβ/CD19-cell depleted HLA-haploidentical transplantation to treat pediatric acute leukemia, learn more about the incidence, clinical characteristics, and survival of malignancy-associated hemophagocytic lymphohistiocytosis in Sweden, and discuss the bone marrow as the primary site of thrombopoiesis. 

In this week's episode we'll discuss the findings from a natural history study of patients with familial platelet disorder with myeloid malignancy, learn more about the role of HEXIM1 as an essential transcription regulator in human erythropoiesis, and discuss the utility of residual disease as a predictor of relapse in CML patients stopping TKI therapy.

Pink Sheet reporter and editors discuss the FDA acknowledging reports of malignancies in patients who received CAR-T cell immunotherapies (:35), the agency's policy for using background music in direct-to-consumer advertising (7:27), and the FDA's new incoming principal deputy commissioner (13:44). More On These Topics From The Pink Sheet CAR-T Malignancy Reports Could Temper Excitement For Use Beyond Oncology: https://pink.citeline.com/PS149420/CAR-T-Malignancy-Reports-Could-Temper-Excitement-For-Use-Beyond-Oncology Background Music During Risk Segment Of Rx Drug Ads: FDA Explains Its Policy: https://pink.citeline.com/PS149411/Background-Music-During-Risk-Segment-Of-Rx-Drug-Ads-FDA-Explains-Its-Policy US FDA Chief Scientist Bumpus Will Become Principal Deputy Commissioner: https://pink.citeline.com/PS149428/US-FDA-Chief-Scientist-Bumpus-Will-Become-Principal-Deputy-Commissioner

Full article: https://www.ajronline.org/doi/10.2214/AJR.23.29826  Hong Linda Li, MD discusses a new article that examines the need for a comprehensive approach that integrates clinical, radiological, and histopathological data for accurate diagnosis and management of adrenal masses.

References Front Immunol. 2019; 10: 14 Cancer Immunol Immunother. 2016 Apr;65(4):441-52 Anal Cell Pathol (Amst).2018; 2018: 787.1814. Molecular Cancer 2020. volume 19, Article number: 39 Cohan, G. 1917. "Over There" https://youtu.be/BYV044H5muI?si=LdANMG6dtXeC14tj --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support

Have you ever wondered about how to treat VTE in malignancy? This episode goes over all the ins and outs of this complex and nuanced topic! Written by Dr. Kevin Yijun Fan, Internal Medicine and reviewed by Dr. Helena Dhamko, (Hematology) and Dr. Ed Etchells (General Internal Medicine).  Infographic by Valarie Kim (Internal Medicine Resident). Support the show

Radiation oncology in GI malignancy (endpoints and stratification) in the JCO

Dr. Rod Quilitz, Lead Pharmacist and Antimicrobial Stewardship Program Coordinator at Moffitt Cancer Center and Research Institute, presents a comprehensive talk on the use of antifungal agents and antivirals in the Malignancy patient. Dr Quilitz begins by reviewing the mechanisms of action of different antifungal drug classes. He next discusses Polyene antifungals, azoles, echinocandins in order and includes information on their structure, indications, spectrum of action, dosing information, and toxicities. Lastly, Dr Quilitz discusses antivirals used in the treatment of Herpesvirus family infections, including acyclovir, ganciclovir, foscarnet, cidofovir, and others.

Cancer inherently increases the risk of Deep Vein Thrombosis and Pumlmonary Embolism. This is merely a nuisance for some, while others experience significant morbidity, leading to hemodynamic instability and potential death. Historically known as "the great masquerader" with pulmonary embolisms, we explore signs, symptoms, and different approaches to treatment. Warfarin remains the original and is still an option for patients, but have better therapies emerged like direct oral anticoagulants (DOACs)? The short answer is yes, but tune in as we dive again into systematic reviews and give you a summarised version of everything you should know.Useful Links:Statpearls DVT: https://www.ncbi.nlm.nih.gov/books/NBK507708/Anticoagulation for thrombus in malignancy: https://www.uptodate.com/contents/anticoagulation-therapy-for-venous-thromboembolism-lower-extremity-venous-thrombosis-and-pulmonary-embolism-in-adult-patients-with-malignancy?search=cancer%20induced%20DVT&source=search_result&selectedTitle=4~150&usage_type=default&display_rank=4For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

Sam talks with writer and historian Paul Street (also on the RefuseFascism.org Editorial Board) about recent events including the fascist attempts to shut down the government, the ouster of Kevin McCarthy from the Speaker of the House, and the increasingly violent threats and promises of vengeance from current frontline candidate for president and as-yet unconvicted coup plotter Donald Trump. Follow Paul on his Substack and read his latest article, Nether the Fascist Trump Nor Imperialist Biden Mentioned in this episode: America needs to talk about the right's ‘Red Caesar' plan for U.S. dictatorship by Will Bunch Trump's Bloody Campaign Promises by David Remnick Related episodes: Fascism In America: Past and Present Trump Indicted and Media Complicity in the Rise of Fascism The Fantasy of the Reasonable Republican  How to help the show? Rate and review wherever you get your podcasts; share with your friends! Get involved at RefuseFascism.org. We're still on Twitter (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@RefuseFascism⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠) and other social platforms including Threads, Mastodon and Bluesky. Send  your comments to samanthagoldman@refusefascism.org or ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@SamBGoldman⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Record ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠a voice message for the show here. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Connect with the movement at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠RefuseFascism.org⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and support: · ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠paypal.me/refusefascism⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ · ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠donate.refusefascism.org⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ · ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠patreon.com/refusefascism⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Music for this episode: Penny the Snitch by Ikebe Shakedown --- Send in a voice message: https://podcasters.spotify.com/pod/show/refuse-fascism/message

Dr. Refky Nicola discusses the potential role of contrast-enhanced US in the differentiation of malignant and benign lesions with Dr. Edward Grant.   Contrast-enhanced US to Improve Diagnostic Performance of O-RADS US Risk Stratification System for Malignancy. Yuan et al. Radiology 2023; 308(2):e223003.   Adding Contrast-enhanced US to O-RADS: A Route to Improved Specificity? Grant. Radiology 2023; 308(2):e231483.

Join us as we review recent articles and news featured in The DIGEST #43 and #44, including bempedoic acid to lower cardiovascular risk, Alpha-Gal Syndrome, tick bites and meat allergy, orforglipron an oral GLP1 agonist for weight loss, zuranolone for postpartum depression, DOACs for VTE of malignancy, monoclonal antibodies (mAbs) for Dementia, cytisinicline for smoking cessation, and two kiwis a day for constipation. Fill your brain hole with a delicious stack of hotcakes! Featuring Drs. Paul Williams (@PaulNWilliamz), Nora Taranto (@norataranto), and Matt Watto (@doctorwatto). Claim free CME for this episode at curbsiders.vcuhealth.org! Episodes | Subscribe | Spotify | Swag! |Mailing List | Contact | Free CME! Credits Written and Hosted by: Nora Taranto MD; Paul Williams, MD, FACP, Matthew Watto MD, FACP Cover Art: Matthew Watto MD, FACP Reviewers: Nora Taranto MD; Paul Williams, MD, FACP, Matthew Watto MD, FACP Technical Production: Pod Paste Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Sponsor: Netsuite Download NetSuite's popular KPI Checklist, designed to give you consistently excellent performance for free, at NetSuite.com/CURBSIDERS Sponsor: Locumstory  Get a comprehensive view of locums and decide if it's right for you at locumstory.com. Sponsor: Grammarly  Go to grammarly.com/GO to download for FREE today. Sponsor: Pathway Download the Pathway app today by visiting pathway.md Show Segments Intro, disclaimer Bempedoic Acid for CV risk reduction DOACs to prevent recurrent VTE of malignancy Cytisinicline for smoking cessation Alpha-Gal Syndrome, tick bites, and meat allergy Zuranolone for postpartum depression Orforglipron, an oral GLP1 agonist, for weight management mAbs for Alzheimer's dementia Kiwis to prevent constipation Outro

James sits down with Brian and Kyle of Pittsburg based super group Shadow Legion to discuss their debut self-titled album. The discuss blending epic heavy metal with black and death metal elements, balancing clean and harsh vocals and how to make that feel cohesive. They talk about the band's current and former projects including Diabolic, Phyrron, Hate Eternal, Lethal Prayer, MALIGNANCY and Gigan. They discuss the Pittsburg music scene, AI and its role in music and where to eat in Pittsburg. They also talk about DIO: Dreamers Never Die, having a sense of humour in extreme metal, Iron Maiden and their legacy and much more. Listen to and follow Shadow Legion: https://shadowlegion1.bandcamp.com/album/shadow-legion https://www.facebook.com/profile.php?id=100083580457921 https://www.instagram.com/shred_storm_pr/ https://open.spotify.com/album/58S3ACqJ8L6RtwbMMAR6Bg?si=kG-ZXsWTTvy2aBxrxKMA0Q

Dr. Ana Velez, Professor of Medicine and Infectious Diseases Clinician at Moffitt Cancer Center and Research Institute, discusses the association between malignancies and Human Immunodeficiency Virus Infection. Dr. Velez begins by discussing that factors in HIV disease and stimulate the formation of cancers. Next, Dr. Velez discusses AIDS defining maligancies, including Kaposi sarcoma, Non-Hodgekin Lymphoma, and cervical cancer. Dr. Velez then discusses lung cancer and head and neck cancer in HIV disease, and speculates on the reasons for poorer outcomes in these patients. Lastly, state of the art therapies for malignancy treatment in HIV patients are discussed, including stem cell transplantation and CAR-T therapy.

In this episode I bring to you... "A Case of Malignancy in a Lumbar Spine Pain Patient."1.  Review of a patient scenario with chronic LBP.2.  Identify the specific “red flags” associated with this patient situation.3.  Brief review of lumbar spine “red flags”.4.  Bring some tissues for this one.  This story might tug at your heart a little. Or you may even get angry to hear how it turned out.  Support OEP today!Welcome to our new sponsor!  Chattanooga.  To check out all they have to offer, trial modalities, have your questions answered about shockwave therapy, high level laser, radial pressure wave, connect with them HERE!Want to join the OEP community? Click HERE to jump onto our email list. SUBSCRIBE at the bottom of the page.Ask me your ortho evaluation questions and I will answer them on the show: paul@orthoevalpal.comCome visit our WEBSITE!! Click HERE to check it outGet our downloadable 1.5 hour shoulder anatomy with cadaver dissection lectureGet our downloadable 7.5 hour cervical and lumbar continuing ed courseGet our downloadable 6.0 hour shoulder continuing ed courseBe sure to "follow" us on our new Facebook PageI finally made it to Instagram. Stop by and check us outAre you looking for One on one Coaching? We have it!Be sure to check out our 500+ videos on our YouTube Channel called Ortho Eval Pal with Paul Marquis#lumbarspine #lumbarredflags #podcasts #PTpodcast #medical #health #orthopedics #Physicaltherapy #running #DPT #Medicalproviders #sportsmedicine #athletictraining#chiropracticSupport the show Thanks for listening! If you like our podcast, be sure to check out more of our great content at OrthoEvalPal.com, Instagram and Youtube. We'd love a rating or review on your podcast platform. And, as always, be kind to each other and take care!!

Drs Sandhya Srinivas and Rana R. McKay discuss bone health and survivorship, including risk factors and potential side effects with androgen deprivation therapy in patients with prostate cancer. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/988732). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Metastases in Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/29661810/ Do Dietary Calcium and Vitamin D Matter in Men With Prostate Cancer? https://pubmed.ncbi.nlm.nih.gov/29765146/ Zoledronic Acid: A Review of Its Use in the Management of Bone Metastases and Hypercalcaemia of Malignancy https://pubmed.ncbi.nlm.nih.gov/12558465/ Denosumab in Osteoporosis https://pubmed.ncbi.nlm.nih.gov/24289327/ Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/23863050/ Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/28030702/ The Prevention of Fragility Fractures in Patients With Non-Metastatic Prostate Cancer: A Position Statement by the International Osteoporosis Foundation https://pubmed.ncbi.nlm.nih.gov/29088899/ Decreased Fracture Rate by Mandating Bone Protecting Agents in the EORTC 1333/PEACEIII Trial Combining Ra223 With Enzalutamide Versus Enzalutamide Alone: An Updated Safety Analysis. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.5002 Addition of Radium-223 to Abiraterone Acetate and Prednisone or Prednisolone in Patients With Castration-Resistant Prostate Cancer and Bone Metastases (ERA 223): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/30738780/

VOIVOD drummer Michel "Away" Langevin and RAVEN frontman John Gallagher join us on this week's Loaded Radio Podcast. This week's edition of THE LOADED RADIO PODCAST features two veterans within the genre of heavy metal. Michel "Away" Langevin from Canadian experimental thrashers VOIVOD as well as frontman John Gallagher from New Wave Of British Heavy Metal icons RAVEN. In 2023, VOIVOD are commemorating their remarkable 40-year journey with a momentous milestone: the release of the special anniversary studio album titled "Morgöth Tales," which arrived on July 21 through Century Media Records. This album, once again recorded and mixed by Francis Perron at RadicArt Studio, mastered by Maor Appelbaum, and produced by VOIVOD themselves, showcases a captivating collection of fresh studio re-recordings. The band's current lineup carefully handpicked these selections, delving into their extensive and diverse musical catalog from 1984 to 2003. Additionally, "Morgöth Tales" features an all-new song and the eponymous title track, adding another layer of excitement. Hailing from Jonquière, Québec, VOIVOD is a prominent Canadian heavy metal band. Over the years, their musical style has undergone various transformations since their formation in the early 1980s. Initially rooted in speed metal, VOIVOD incorporated elements of progressive metal and thrash metal, forging a distinct and innovative metal sound. They are widely recognized as one of the "big four" Canadian thrash metal bands, alongside SACRIFICE, RAZOR, and ANNIHILATOR. Throughout their illustrious career, VOIVOD has attained significant influence and acclaim, making them one of the most revered metal bands from the 1980s. Their impact has transcended boundaries, garnering praise and inspiring numerous bands across a wide array of genres. The second portion of the show features a talk with John Gallagher from RAVEN who have their new studio album "All Hell's Breaking Loose" available now. RAVEN demonstrated incredible productivity from the early '80s to the late '90s, consistently delivering a new album every year or two. Following a hiatus that lasted a decade, they resumed releasing fresh material in 2010. Their latest offering, titled "All Hell's Breaking Loose," proudly stands as their fifteenth studio album. The foundation of RAVEN has always rested upon the talented Gallagher brothers: John on vocals and bass, and Mark on guitar. Throughout their journey, the band has seen several drummers come and go, but since 2018, they have been accompanied by the skilled Mike Heller (known for his work with FEAR FACTORY and MALIGNANCY). Heller's presence on board marks his second album collaboration with RAVEN, with "All Hell's Breaking Loose" being recorded at his studio in Los Angeles. In 2023, RAVEN's musical direction remains faithful to the path they carved during the glorious era of the New Wave of British Heavy Metal (NWOBHM). However, they harness their decades of experience and combine it with modern production techniques when crafting the songs that adorn "All Hell's Breaking Loose." This fusion allows them to uphold their musical roots while embracing the advancements of the present day.

In this episode, host Dr. Sarah Wise speaks with Dr. Daniel Beswick. They discuss his recently published article: Long-term quality of life after treatment in sinonasal malignancy: A prospective, multicenter study. Read the article in International Forum of Allergy and Rhinology. Listen and subscribe for free on Apple Podcasts , Google Podcasts and Subscribe on Android.

The Cancer Advances podcast is joined by Abhay Singh, MD, MPH, a physician with the Department of Hematology and Medical Oncology at Cleveland Clinic to talk about his study, which aimed to identify risk factors for secondary malignancy in breast cancer survivors. This study was presented at the American Society of Hematology (ASH) 2022 annual meeting. Listen as Dr. Singh explains how he explored the different risk factors, such as G-CSF exposure, how the CHIP Clinic might be able to monitor patients, and the long-term goal to figure out which therapies patients should try to avoid.

The palm is ~0.5% TBSA - Insurance companies denying coverage - Malignancy risk in JAK inhibitors - MACE risk in JAK inhibitors - Oral azoles for head-and-neck dermatitis - Luke's PDPC course and the Intermountain Derm Society meeting: https://registration.socio.events/e/idspdpc23/promo-codes/ATTENDEE Connect with us! - Web: https://dermaspherepodcast.com/ - Twitter: @DermaspherePC - Instagram: dermaspherepodcast - Facebook: https://www.facebook.com/DermaspherePodcast/ - Check out Luke and Michelle's other podcast, SkinCast! https://healthcare.utah.edu/dermatology/skincast/ Luke and Michelle report no significant conflicts of interest… BUT check out our friends at: - Kikoxp.com(a social platform for doctors to share knowledge) - https://www.levelex.com/games/top-derm (A free dermatology game to learn more dermatology!)

Full article: https://www.ajronline.org/doi/abs/10.2214/AJR.22.28396  Mohanned Alnammi, MD discusses a new study evaluating the diagnostic performance of O-RADS US and O-RADS MRI for risk stratification of ovarian and adnexal lesions.

Recently the Endocrine Society published a new clinical practice guideline entitled, “Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline.” What exactly is hypercalcemia of malignancy? What are its symptoms? How is it treated? And what do the guidelines recommend? To help answer these questions, host Aaron Lohr talks with Ghada El-Hajj Fuleihan, MD, MPH, professor of medicine at the American University in Beirut in Lebanon. She is the chair of the Society working group that developed this guideline. Show notes are available at https://www.endocrine.org/podcast/enp68-hypercalcemia-of-malignancy — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

Recently the Endocrine Society published a new clinical practice guideline entitled, “Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline.” What exactly is hypercalcemia of malignancy? What are its symptoms? How is it treated? And what do the guidelines recommend? To help answer these questions, host Aaron Lohr talks with Ghada El-Hajj Fuleihan, MD, MPH, professor of medicine at the American University in Beirut in Lebanon. She is the chair of the Society working group that developed this guideline. Show notes are available at https://www.endocrine.org/podcast/enp68-hypercalcemia-of-malignancy — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

Recently the Endocrine Society published a new clinical practice guideline entitled, “Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline.” What exactly is hypercalcemia of malignancy? What are its symptoms? How is it treated? And what do the guidelines recommend? To help answer these questions, host Aaron Lohr talks with Ghada El-Hajj Fuleihan, MD, MPH, professor of medicine at the American University in Beirut in Lebanon. She is the chair of the Society working group that developed this guideline. For helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

After this episode, listeners should be able to: Understand the basic anatomy, physiology, and function of the small bowel List the types and common locations of small bowel malignancies Recognize risk factors for small bowel cancers Identify the clinical presentations for small bowel malignancies Understand the preoperative workup for diagnosis Describe the surgical treatment for small bowel malignancies

PDF Notes for Episode on Small Bowel Malignancy.

Ep. 108 - Alex Weber (Exist, Svengahli, Obscura, Malignancy) by Cali Death Podcast

What's the one clinical scenario where you can really save a patient's life with a pancreatectomy? An IPMN with high-grade dysplasia! Join the Behind the Knife HPB Team for a deep dive into the complex decision-making surgical management of IPMNs. Learning Objectives In this episode, we review the basics of intraductal papillary mucinous neoplasms, how to evaluate patients with a cystic mass of the pancreas, guidelines for surveillance, and indications for resection. We discuss key concepts such as Worrisome Features and High-Risk Stigmata and how those influence surgical decision-making, and tackle a few of the most challenging scenarios surgeons may face when treating patients with IPMNs.   Hosts: Timothy Vreelant, MD, FACS (@vreelant) is an Assistant Professor of Surgery at the Uniformed Services University of the Health Sciences and Surgical Oncologist at Brooke Army Medical Center Daniel Nelson, DO, FACS (@usarmydoc24) is an Associate Professor of Surgery at the Uniformed Services University of the Health Sciences and Surgical Oncologist at William Beaumont Army Medical Center Connor Chick, MD (@connor_chick) is a PGY-6 General Surgery resident at Brooke Army Medical Center Lexy (Alexandra) Adams, MD, MPH (@lexyadams16) is a PGY-5 General Surgery resident at Brooke Army Medical Center Beth Carpenter, MD (@elizcarpenter16) is a PGY-4 General Surgery resident at Brooke Army Medical Center Links to Papers Referenced in this Episode Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas Pancreatology. 2017 Sep-Oct;17(5):738-753. https://pubmed.ncbi.nlm.nih.gov/28735806/ Number of Worrisome Features and Risk of Malignancy in Intraductal Papillary Mucinous Neoplasm.  J Am Coll Surg. 2022 Jun 1;234(6):1021-1030.  https://pubmed.ncbi.nlm.nih.gov/35703792/ Extent of Surgery and Implications of Transection Margin Status after Resection of IPMNs.  Gastroenterology Research and Practice 2014, 1–10. https://pubmed.ncbi.nlm.nih.gov/25276122/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out other Hepatobiliary Surgery episodes here: https://behindtheknife.org/podcast-category/hepatobiliary/